• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Novartis - Articles and news items

Cardiovascular risk

Novartis invests in Ionis’ therapies to reduce cardiovascular risk

Industry news / 10 January 2017 / Niamh Marriott, Digital Editor

Novartis announced a collaboration and option agreement to license two novel treatments with the potential to significantly reduce cardiovascular risk…

macular degeneration

Novartis’ macular degeneration Phase III trial did not meet endpoint

Industry news / 14 December 2016 / Niamh Louise Marriott, Digital Editor

Novartis’ two pivotal Phase III clinical studies did not meet their primary endpoints to treatment of neovascular age-related macular degeneration…

Novartis’ SMS for Life 2.0 to improve access to medicines in Nigeria

Industry news / 12 December 2016 / Niamh Louise Marriott, Digital Editor

The new and enhanced SMS for Life 2.0 program will now use smartphone and tablet computers to address key operational challenges at peripheral healthcare…

Novartis’ NSCLC study shows 16.6 month progression-free survival

Industry news / 12 December 2016 / Niamh Louise Marriott, Digital Editor

Patients with ALK+ advanced non-small cell lung cancer treated with Zykadia had a median progression-free survival of 16.6 months, compared to placebo…

Novartis’ Phase II antibody trial reduces frequency of sickle cell pain crises

Industry news / 6 December 2016 / Niamh Louise Marriott, Digital Editor

Results from the Phase II study show that SEG101 an anti-P-selectin antibody, reduced the median annual rate of sickle cell-related pain crises by 45.3%…

GSK tops list ranking big pharma’s global access to medicine

Industry news / 14 November 2016 / Niamh Louise Marriott, Digital Content Producer

Read how the 2016 Access to Medicine Index ranks the top 20 pharmaceutical companies on their efforts to improve access to medicine in low- and middle-income countries…

FDA grants priority review for Novartis’ first-line treatment of HR+/HER2- advanced breast cancer

Industry news / 7 November 2016 / Niamh Louise Marriott, Digital Content Producer

The US Food and Drug Administration (FDA) accepted Novartis’ new drug application (NDA) for filing and granted priority review for LEE011 (ribociclib)…

Novartis wins “Discovery of the Decade” and “Best Biotechnology Product” awards

Industry news / 31 October 2016 / Niamh Louise Marriott, Digital Content Producer

Novartis has been awarded the 2016 Prix Galien USA Award “Discovery of the Decade” Award for Best Pharmaceutical Product for the drug Gleevec, as well as…

Patient overall survival still strong three years after Novartis’ melanoma trial

Industry news / 12 October 2016 / Niamh Louise Marriott, Digital Content Producer

45% of patients receiving the combination of Tafinlar + Mekinist (95% CI, 39.1%-49.8%) compared with 31% of patients who received vemurafenib monotherapy…

Novartis’ HR+/HER2- advanced breast cancer trial gives superior progression-free survival

Industry news / 10 October 2016 / Niamh Louise Marriott, Digital Content Producer

The results demonstrate that LEE011 plus letrozole reduced the risk of death or progression by 44%. The combination significantly improved PFS across…

Novartis’ plaque psoriasis drug keeps skin clear 4 years post treatment

Industry news / 4 October 2016 / Niamh Louise Marriott, Digital Content Producer

The aim of Novartis’ plaque psoriasis treatment is clear skin and was achieved by 68.5% of patients at Year 1 and this high rate was maintained to Year 4…

Novartis’ global study shows 57% of psoriasis patients didn’t reach clear skin treatment goal

Industry news / 3 October 2016 / Niamh Louise Marriott, Digital Content Producer

People with the autoimmune disease, psoriasis, also report that they face discrimination, humiliation, and mental illness…

 

Webinar: Understanding ISO Standards: ISO 14644-2:2015 Cleanroom MonitoringFIND OUT MORE
+ +